Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma
المؤلفون المشاركون
Han, Su-xia
He, Chen-chen
Guo, Xi-jing
Ying, Xia
Zhu, Qing
Wang, Jun-lan
Ma, Jin-lu
Zhang, Yuan-yuan
Zhao, Qian
المصدر
Journal of Immunology Research
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-04-17
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Aim.
Sal-like protein 4 (SALL4), is reexpressed in tissues of a subgroup of HCC associated with poor prognosis.
Reports of SALL4 serological levels linked to HCC patients are meager and unclear in the prognosis of this malignancy.
Methods.
Immunohistochemistry and optical microscopy protocols were used to examine the presence of SALL4 in liver tissues from the following patients: 38 HCC, 11 chronic hepatitis B virus (HBV), 13 liver cirrhosis, and 12 healthy controls.
Additionally, enzyme-linked immunosorbent assay (ELISA) was used to measure the SALL4 levels in serum samples isolated from patients as follows: 127 with HCC, 27 with HBV, 24 with liver cirrhosis, and 23 normal controls.
Results.
Analysis of liver tissues sections from HCC patients (18 out 38; 47.4%) showed positive staining for SALL4 and its expression did no correlate with any of the clinicopathologic characteristics.
HCC patients displayed higher levels (50.4%) of SALL4 protein in serum, compared with the three control groups.
Moreover, SALL4 concentration reached the maximum level after one week after treatment and dropped quickly after one month.
These HCC patients showing high SALL4 serum levels had poor prognosis, evidenced by both tumor recurrence and overall survival rate.
Conclusions.
High SALL4 serum levels are a novel biomarker in the prognosis of HCC patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Han, Su-xia& Wang, Jun-lan& Guo, Xi-jing& He, Chen-chen& Ying, Xia& Ma, Jin-lu…[et al.]. 2014. Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma. Journal of Immunology Research،Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1040805
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Han, Su-xia…[et al.]. Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma. Journal of Immunology Research No. 2014 (2014), pp.1-7.
https://search.emarefa.net/detail/BIM-1040805
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Han, Su-xia& Wang, Jun-lan& Guo, Xi-jing& He, Chen-chen& Ying, Xia& Ma, Jin-lu…[et al.]. Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma. Journal of Immunology Research. 2014. Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1040805
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1040805
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر